Monitoring response of advanced Merkel cell carcinoma to Avelumab with 18F-FDG PET/CT

  • Cecilia VellaniEmail author
  • Daniela D’Ambrosio
  • Luca Licata
  • Ilaria Vacchieri
  • Antonio Bernardo
  • Giuseppe Trifirò
Image of the Month


  1. 1.
    Kaufman H, Russel J, Hamid O, Bhatia S, Terheyden P, D’Angelo S, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.CrossRefGoogle Scholar
  2. 2.
    Bharmal M, Marrel A, Hennessy M, Fofana F, Lambert J, Arnould B. Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights. J Comp Eff Res. 2018.
  3. 3.
    Esgghi N, Lundeen TF, MacKinnon L, Avery R, Kuo PH. 18F-FDG PET/CT for monitoring response of Merkel cell carcinoma to the novel programmed cell death ligand 1 inhibitor Avelumab. Clin Nucl Med. 2018;43:e142–4.Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Nuclear Medicine UnitICS Maugeri SpA SB IRCCSPaviaItaly
  2. 2.Medical Physics DepartmentICS Maugeri SpA SB IRCCSPaviaItaly
  3. 3.Operative Unit of Medical OncologyICS Maugeri SpA SB IRCCSPaviaItaly
  4. 4.School of Medical PhysicsUniversity of MilanMilanItaly

Personalised recommendations